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GLP-1R NT purification and binding
To isolate a GLP-1R NT domain that is produced
in mammalian cells and does not require a detergent
solubilization step, COS-7 cells were transfected
with the construct pSec NT GLP-1R (Fig. 4A).
Since this construct is designed to produce a
secretable protein, in theory the NT domain should
accumulate in culture media. Three days post-
transfection, soluble protein containing the myc-
(His)6 tag was purified using an Ni
2+-NTA
Superflow column and eluted with increasing
concentrations of imidazole (50–500 mM). The
elution fractions were analysed by Western blotting
using anti-myc antibody. As shown in Fig. 4B, a
strong protein band of molecular mass 30 kDa
(lanes 2 and 3) was observed in the eluate fractions
(50 and 200 mM imidazole), but was not present in
control cell media, unpurified media or washing
buffer. Since the deduced molecular masses of the
NT domain and the vector fusion protein were
approximately 22 kDa and 5 kDa respectively, the
larger apparent size of the protein could be
attributed to post-translational glycosylation. Ad-
ditionally, the appearance of the 80 kDa band may
represent non-specific binding with components
present in the culture medium (since it was also
present in the control fraction).
To determine if the purified NT protein obtained
from a mammalian expression system was able to
bind GLP-1, the NT-domain protein was absorbed
onto Ni2+-NTA beads by using the procedure
described in the Materials and Methods (see Fig.
4C) to perform a competitive displacement assay.
When compared with the non-specific binding
(2668!276 c.p.m./tube, n=3), represented by the
counts obtained from the control beads attached to
an equivalent amount of expressed PSA control
 2. Schematic representation of the predicted structure of the rat GLP-1R. The GLP-1 receptor is predicted
to contain an NT, three EC and IC loops, seven TM domains and a carboxy-terminal (CT) tail. Amino acids are
identified by the one-letter code. , represent the amino acids that were substituted by A in this study. represent
the leader sequence.
  and others · Glucagon-like peptide-1 receptor binding326
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Fig. 3. Predicted arrangement of the SecR family transmembrane domain using the sequence of the rat GLP-1 receptor (GLPR_RAT; see 
legend to Fig. 2 for consensus prediction conventions). 
diction with the buried positions shown with black squares 
and the lipid accessible positions shown with asterisks. If 
each sequence is represented as a helical wheel, it can be 
seen that, in general, the predicted buried and lipid-accessible 
faces of the helices are mutually exclusive (Fig. 3) with only 
two exceptions. In the first of these, there is an overlap be-
tween the buried and lipid-accessible faces on TM2. However, 
in this case the accuracy of the lipid-accessible prediction is 
questionable since it is based upon the presence of an arginine 
residue at position 2.15 of the human growth hormone-releas-
ing hormone-receptor (GRFR_HXJMAN). This is likely to be 
a sequence error since a second sequence for the same human 
receptor (A45367) suggests that this residue is an alanine as it 
is in the rat, mouse and pig homologues. Further evidence 
that this position is buried comes from mutagenesis work 
on the opossum PTH receptor in which the Ser233-Ala sub-
stitution results in a greater than 50% reduction of the max-
imal stimulation of adenylyl cyclase activity as well as a right-
ward shift in the dose response curve [26]. The second overlap 
of the predicted buried and lipid-accessible faces is in TM6, 
although the overlap is of only one residue. This may indicate 
the direction of the tilt of TM6 since it suggests that the 
extracellular C-terminus of the helix tilts away from the bun-
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